Why Is AT&T Stock Dropping?
The telecommunications giant AT&T Inc. (NYSE:T) has perhaps surprisingly eclipsed…
Buy
56
BIO Quote, Financials, Valuation and Earnings
Last price:
$342.96
Seasonality move
:
8.24%
Day range:
$341.38 - $345.76
52-week range:
$262.12 - $387.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.77x
P/B ratio:
1.28x
Volume:
122.4K
Avg. volume:
169.7K
1-year change:
12.59%
Market cap:
$9.6B
Revenue:
$2.7B
EPS (TTM):
-$27.33
Analysts' Opinion
-
Consensus RatingBio-Rad Laboratories has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 2 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $404.33, Bio-Rad Laboratories has an estimated upside of 18.09% from its current price of $342.41.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $315.00 representing 100% downside risk from its current price of $342.41.
Fair Value
-
According to the consensus of 4 analysts, Bio-Rad Laboratories has 18.09% upside to fair value with a price target of $404.33 per share.
BIO vs. S&P 500
-
Over the past 5 trading days, Bio-Rad Laboratories has underperformed the S&P 500 by -2.64% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Bio-Rad Laboratories does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Bio-Rad Laboratories has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Bio-Rad Laboratories reported revenues of $649.7M.
Earnings Growth
-
Bio-Rad Laboratories has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Bio-Rad Laboratories reported earnings per share of $23.34.
Enterprise value:
9.2B
EV / Invested capital:
--
Price / LTM sales:
3.77x
EV / EBIT:
--
EV / Revenue:
3.55x
PEG ratio (5yr expected):
-0.03x
EV / Free cash flow:
40.96x
Price / Operating cash flow:
43.50x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$1.4B
Return On Assets:
-6.82%
Net Income Margin (TTM):
-30.18%
Return On Equity:
-9.62%
Return On Invested Capital:
-8.38%
Operating Margin:
9.92%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $2.8B | $2.7B | $2.6B | $632.1M | $649.7M | |
| Gross Profit | $1.6B | $1.5B | $1.4B | $335.7M | $355.9M | |
| Operating Income | $481.8M | $353.6M | $306M | $90.9M | $64.5M | |
| EBITDA | -$7.7B | $5.7M | -$806.5M | $186.8M | $912.7M | |
| Diluted EPS | -$201.62 | -$5.85 | -$27.33 | $3.64 | $23.34 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.3B | $2.5B | $3.1B | $3.1B | $3.1B | |
| Total Assets | $12B | $20B | $12.1B | $11.9B | $10.6B | |
| Current Liabilities | $986.7M | $649.9M | $570.7M | $558.2M | $497.9M | |
| Total Liabilities | $3.2B | $4.6B | $3.6B | $3.5B | $3.1B | |
| Total Equity | $8.8B | $15.3B | $8.5B | $8.4B | $7.5B | |
| Total Debt | $427.2M | $1.2M | $1.2B | $1.2B | $1.2B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $285.7M | $373.6M | $412.1M | $97.7M | $163.6M | |
| Cash From Investing | -$1.7B | -$110.5M | -$57.5M | -$9.5M | -$55.6M | |
| Cash From Financing | $1.1B | -$311.6M | -$393.2M | -$26.6M | -$96M | |
| Free Cash Flow | $151.5M | $222.9M | $223.8M | $53.6M | $100M | |
BIO
Sector
Market Cap
$9.6B
$45.2M
Price % of 52-Week High
88.25%
46.55%
Dividend Yield
0%
0%
Shareholder Yield
4.3%
-0.75%
1-Year Price Total Return
12.59%
-33.5%
Beta (5-Year)
0.899
0.747
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$344.09
200-day SMA
Buy
Level
$317.22
Bollinger Bands (100)
Buy
Level
323.43 - 349.97
Chaikin Money Flow
Buy
Level
25.3M
20-day SMA
Buy
Level
$335.32
Relative Strength Index (RSI14)
Buy
Level
53.67
ADX Line
Buy
Level
21.17
Williams %R
Neutral
Level
-39.5
50-day SMA
Buy
Level
$339.40
MACD (12, 26)
Buy
Level
2.40
25-day Aroon Oscillator
Buy
Level
60
On Balance Volume
Neutral
Level
23.5M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.8558)
Buy
CA Score
(Annual)
Level (0.3067)
Buy
Beneish M-Score
(Annual)
Level (-2.8448)
Buy
Momentum Score
Level (6)
Sell
Ohlson Score
Level (1.0242)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Stock Forecast FAQ
In the current month, BIO has received 2 Buy ratings 2 Hold ratings, and 0 Sell ratings. The BIO average analyst price target in the past 3 months is $404.33.
-
Where Will Bio-Rad Laboratories Stock Be In 1 Year?
According to analysts, the consensus estimate is that Bio-Rad Laboratories share price will rise to $404.33 per share over the next 12 months.
-
What Do Analysts Say About Bio-Rad Laboratories?
Analysts are divided on their view about Bio-Rad Laboratories share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Bio-Rad Laboratories is a Sell and believe this share price will drop from its current level to $315.00.
-
What Is Bio-Rad Laboratories's Price Target?
The price target for Bio-Rad Laboratories over the next 1-year time period is forecast to be $404.33 according to 4 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is BIO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Bio-Rad Laboratories is a Leans Bullish. 2 of 4 analysts rate the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of BIO?
You can purchase shares of Bio-Rad Laboratories via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Bio-Rad Laboratories shares.
-
What Is The Bio-Rad Laboratories Share Price Today?
Bio-Rad Laboratories was last trading at $342.96 per share. This represents the most recent stock quote for Bio-Rad Laboratories. Yesterday, Bio-Rad Laboratories closed at $342.41 per share.
-
How To Buy Bio-Rad Laboratories Stock Online?
In order to purchase Bio-Rad Laboratories stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is American Express Stock Going Lower?
American Express Company (NYSE:AXP) has long been a Buffett favorite…
Cigna vs Costco Stock: Which Is Best?
Cigna and Costco don’t usually go hand in hand but…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 38x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 115x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
45
QMCO alert for Jan 18
Quantum [QMCO] is down 15.61% over the past day.
Buy
51
QRVO alert for Jan 18
Qorvo [QRVO] is up 14.47% over the past day.
Sell
31
ATEX alert for Jan 18
Anterix [ATEX] is up 11.14% over the past day.
